Last reviewed · How we verify
Aminopan (SOMATOSTATIN)
Aminopan (generic name: SOMATOSTATIN) is a somatostatin drug. It is currently in Phase 3 development.
Aminopan works by binding to somatostatin receptors on cells, which blocks the release of hormones and growth factors.
Aminopan is a small molecule. Its exact clinical uses and mechanism of action are not specified in the provided information.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SOMATOSTATIN |
|---|---|
| Drug class | somatostatin |
| Target | Somatostatin receptor type 1, Somatostatin receptor type 2, Somatostatin receptor type 3 |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine your body has a 'brake' system that regulates the release of hormones and growth factors. Aminopan acts like a key that fits into this brake system, preventing the release of these substances and slowing down certain bodily processes.
Approved indications
Common side effects
- Administration site abscess
- Administration site discharge
- Administration site odour
- Administration site induration
- Administration site haemorrhage
- Gastric varices
- Injection site cyst
- Buttock injury
- Injection site paraesthesia
- Carcinoid tumour
- Portal hypertension
Key clinical trials
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors (PHASE2)
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (PHASE3)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (PHASE1)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1,PHASE2)
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aminopan CI brief — competitive landscape report
- Aminopan updates RSS · CI watch RSS
Frequently asked questions about Aminopan
What is Aminopan?
How does Aminopan work?
What is the generic name of Aminopan?
What drug class is Aminopan in?
What development phase is Aminopan in?
What are the side effects of Aminopan?
What does Aminopan target?
Related
- Drug class: All somatostatin drugs
- Target: All drugs targeting Somatostatin receptor type 1, Somatostatin receptor type 2, Somatostatin receptor type 3
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing